Analyst Price Targets — MDLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 7:48 pm | Michael Cherny | Leerink Partners | $56.00 | $48.18 | TheFly | Medline price target raised to $56 from $48 at Leerink |
| February 25, 2026 7:45 pm | — | Stifel Nicolaus | $55.00 | $48.18 | TheFly | Medline price target raised to $55 from $46 at Stifel |
| February 25, 2026 6:37 pm | — | Evercore ISI | $55.00 | $49.38 | TheFly | Medline price target raised to $55 from $50 at Evercore ISI |
| February 5, 2026 2:47 pm | — | Tigress Financial | $55.00 | $45.01 | TheFly | Medline initiated with a Buy at Tigress Financial |
| January 21, 2026 12:16 pm | David Larsen | J.P. Morgan | $55.00 | $43.17 | TheFly | Medline price target raised to $55 from $50 at BTIG |
| January 12, 2026 1:39 pm | — | Barclays | $50.00 | $41.65 | TheFly | Medline initiated with an Overweight at Barclays |
| January 12, 2026 1:17 pm | — | BNP Paribas | $38.00 | $42.19 | TheFly | Medline initiated with a Neutral at BNP Paribas |
| January 12, 2026 12:53 pm | — | Wolfe Research | $47.00 | $41.88 | TheFly | Medline initiated with an Outperform at Wolfe Research |
| January 12, 2026 12:42 pm | — | Deutsche Bank | $40.00 | $40.52 | TheFly | Medline initiated with a Hold at Deutsche Bank |
| January 12, 2026 11:49 am | — | Wells Fargo | $42.00 | $40.52 | TheFly | Medline initiated with an Equal Weight at Wells Fargo |
Latest News for MDLN
NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) have commenced an underwritten public offering of 75,000,000 shares of Medline's Class A common…
Medline Inc (NASDAQ: MDLN) reported mixed results for the fourth quarter on Wednesday.
Medline Inc. (MDLN) Q4 2025 Earnings Call Transcript
NORTHFIELD, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care2, today reported its operating results for the three months and full year ended December 31, 2025.
MDLN is set to report first earnings as a public company, with Prime Vendor growth and brand mix in focus ahead of Q4 results.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MDLN.
U.S. House Trading
No House trades found for MDLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.